The natural history of patients with compensated cirrhosis and elevated hepatic venous pressure gradient
Portal Hypertension & Cirrhosis · 2022
DOI: 10.1002/poh2.27 ↗Kurz gefasst
Fachartikel in der Zeitschrift Portal Hypertension & Cirrhosis, 2022. Verfasst von Andrew Wortham und 2 weiteren Autor:innen. Beteiligte Einrichtung: Digestive Disease Research Center, Medical University of South Carolina, Charleston, SC 29425, USA. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Institute of General Medical Sciences.
Abstract (Originalsprache)
Aims
Portal hypertension is a major complication of liver cirrhosis. Hepatic venous pressure gradient (HVPG) appears to be one of the best surrogates of clinical outcomes. However, the utility of elevated HVPG in predicting subsequent clinical decompensation is unclear.
Methods
We analyzed 410 patients who underwent HVPG assessment between 2014 and 2018. Of these, we identified and analyzed 20 patients with HVPG >12 mmHg without evidence of clinical decompensation (defined as ascites, nonbleeding esophageal varices or bleeding esophageal varices, hepatic encephalopathy, hepatopulmonary syndrome, or hepatic hydrothorax). Additionally, we compared this group to 40 randomly selected cirrhotic patients with HVPG >12 mmHg with signs of clinical decompensation. Clinical events were subsequently assessed (mean = 33 months) after HVPG measurement.
Results
Patients with high HVPG without evidence of clinical decompensation had a significantly lower model for end‐stage liver disease (MELD) scores (8 ± 4) compared to decompensated patients (13 ± 8, p = 0.05). HVPG measurements were similar in compensated (17 ± 6 mmHg) and decompensated (18 ± 4 mmHg) patients. Over follow‐up for 33 months, 8/20 compensated patients had a decompensating event and neither MELD (8 and 8, respectively) nor HVPG (17 and 18 mmHg, respectively) differentiated patients who remained compensated versus those that decompensated. Serum albumin at the time of HVPG measurement was significantly higher in patients who remained compensated than those with a decompensating event (3.5 vs. 2.6 g/dl, respectively, p = 0.05).
Conclusions
A small, unique, population of cirrhotic patients with substantially elevated HVPG appear to remain free of complications over long‐term follow‐up.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Digestive Disease Research Center, Medical University of South Carolina, Charleston, SC 29425, USA.
Förderung
- National Institute of General Medical Sciences
Zitieren
APA
Wortham, A., Khalifa, A., & Rockey, D. C. (2022). The natural history of patients with compensated cirrhosis and elevated hepatic venous pressure gradient. Portal Hypertension & Cirrhosis. https://doi.org/10.1002/poh2.27
Vancouver
Wortham A, Khalifa A, Rockey DC. The natural history of patients with compensated cirrhosis and elevated hepatic venous pressure gradient. Portal Hypertension & Cirrhosis. 2022. doi:10.1002/poh2.27
BibTeX
@article{Wortham2022,
author = {Wortham, Andrew and Khalifa, Ali and Rockey, Don C},
title = {The natural history of patients with compensated cirrhosis and elevated hepatic venous pressure gradient},
journal = {Portal Hypertension & Cirrhosis},
year = {2022},
doi = {10.1002/poh2.27}
}
EUVIMED